Cartherics strengthens global position with new Chinese patent for immune cell therapy

Cartherics Pty Ltd, a Melbourne based biotechnology company focused on developing off the shelf immune cell therapies for women’s health, has achieved an important milestone with the granting of a Chinese patent for its innovative approach to enhancing immune cell function.

The patent covers induced pluripotent stem cells with a targeted knockout of the adenosine A2A receptor. This receptor plays a key role in limiting immune activity within solid tumours. By removing it from natural killer cells, Cartherics aims to maintain cell activity in the tumour microenvironment, improving immune response and potentially boosting the effectiveness of therapies for cancers such as ovarian and triple negative breast cancer.

Cartherics Chief Executive Officer Professor Alan Trounson AO said gene editing is central to the company’s mission to overcome solid tumours. “Our strategy is to edit critical genes to allow immune cells to function as intended in combating cancer. Blocking the A2A receptor is a significant addition to our approach,” he said.

The new patent strengthens Cartherics’ intellectual property portfolio and expands its footprint in China, a market with significant commercial opportunity. It also supports the company’s progress in advancing a pipeline of therapies that target cancers and other diseases with high unmet clinical need, including endometriosis and Alzheimer’s disease.

Learn more about Cartherics at https://cartherics.com